The oligosaccharides in IgG have a complex biantennary structure, consisting of a trimannosyl core (Man 3 GlcNAc 2 -Asn) with or without core L-fucose (Fuc), bisecting N-acetylglucosamine (GlcNAc), galactose (Gal) and sialic acid (Fig.  1A) . [2] [3] [4] [5] Both the structure and composition of the oligosaccharides are known to play an important role in the immunological functions of antibodies. Especially, antibody-dependent cellular cytotoxicity (ADCC), a lytic attack on antibodytargeted cells triggered by the binding of the Fc region to lymphocyte receptors (FcgRs), is influenced by the oligosaccharide feature in the Fc region, and the elimination of all oligosaccharides from IgG results in the full depletion of ADCC activity. In addition, sugar components in the oligosaccharide such as galactose, 6,7) bisecting-GlcNAc 8, 9) and fucose 10, 11) have also been shown to affect ADCC activity.
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While many researchers have noted the great importance of oligosaccharide structure on antibody functions, we have demonstrated that fucose is the most critical component to ADCC activity. We showed that non-fucosylation of a humanized anti-interleukin 5 receptor antibody and an anti-CD20 antibody lead to 50-fold or higher elevation of the activity. In addition, elevation of ADCC activity by non-fucosylation has been reported for a humanized anti-HER2 IgG1 and a humanized anti-IgE IgG1, based on augmented binding affinity to FcgRIIIa receptor. [10] [11] [12] Therefore, the composites which predominantly contains non-fucosylated antibody species are thought to be more effective in anti-cancer antibody therapies. As a stable production technology of such composites, we have already reported a fucosyltransferase knockout (FUT8 Ϫ/Ϫ ) Chinese hamster ovary (CHO) cell line. 13) FUT8 encodes an a-1,6-fucosyltransferase that catalyzes sugar transfer from guanosine 5Ј-diphosphate (GDP)-fucose to N-acetylglucosamine (GlcNAc) in an a-1,6 linkage. Thus, the FUT8 Ϫ/Ϫ CHO cell line can stably produce non-fucosylated antibodies with high-ADCC activity.
With the exception of antibody composites produced by these FUT8
Ϫ/Ϫ CHO cells, almost all therapeutic antibodies on the market as well as many investigational antibodies under development are now produced by FUT8-positive cells like conventional CHO, NS0 and SP2/0 cells. These antibody composites contain low amounts of non-fucosylated species. To elevate ADCC activity, the purification of non-fucosylated antibodies has been achieved for the material produced by YB2/0 cells using Lens culinaris agglutinin (LCA) lectinaffinity chromatography.
11) The resulting content of non-fucosylated oligosaccharides was reported to be approximately 50%. However, it is difficult to enrich non-fucosylated antibodies from the materials produced by CHO cells or SP2/0 cells by means of the same method, because these materials contain significant amounts of high-mannose antibody species (Fig. 1) . 14, 15) They are enriched to the same unbound fraction as the non-fucosylated antibody species through LCA lectin chromatography, since LCA has a specificity only for fucose-containing oligosaccharides.
In the present study, we tried to purify antibody fractions containing predominantly non-fucosylated species from commercially available therapeutic antibody material. AntiHer2/neu antibody (Herceptin TM ), which is produced by a typical manufacturing system using the CHO cell line, was chosen as a model; its non-fucosylated species content has been confirmed to be very low. 11) To elevate the content of non-fucosylated antibody species, we combined two column chromatography techniques, using columns of Concanavalin A (Con A), which preferentially binds to high-mannose oligosaccharides, and LCA, which preferentially binds to fucose-containing oligosaccharides. We hypothesized that high-mannose species could be efficiently removed by the Con A column, and that the resulting fraction could be subjected to the LCA column to obtain a composite with elevated non-fucosylated species. This procedure should make it possible to obtain high-ADCC composites very easily from any antibody source independent of manufacturing systems.
MATERIALS AND METHODS

Materials and
Reagents a-Methyl-D-mannoside and tris(hydroxymethyl)aminomethan (Tris) were purchased from Nacalai Tesque (Kyoto, Japan). Sodium chloride was from Wako Pure Chemicals (Osaka, Japan). Sodium hydroxide was from Kanto Chemical (Tokyo, Japan). Other chemicals were of analytical grade unless otherwise indicated.
Human anti-Her2/neu IgG1 (Herceptin TM ) is a product from Genentech, Inc. (South San Francisco, CA, U.S.A.). It was used as a typical antibody composite produced by conventional process using CHO cell line.
Equipment Chromatography was performed using a LC-6A HPLC system with an ultraviolet detector (Shimadzu, Kyoto, Japan). Absorbance at UV 280 nm was monitored to fractionate the eluate. Oligosaccharide profile of the purified IgG fraction was characterized by matrix-assisted laser desorption/ionization time-of-flight mass (MALDI-TOF MS) spectrometry using Reflex III spectrometer (Bruker Daltoniks GmbH, Germany).
Lectin Affinity Chromatography Con A lectin affinity chromatography was used for separation of antibody species based on the affinity to high-mannose oligosaccharides. Con A-agarose resin (HONEN, Tokyo, Japan) was packed to an empty column (4 ml, 10ϫ50 mm; GE Healthcare Biosciences) and equilibrated with 50 mM Tris-H 2 SO 4 , 0.5 M NaCl at pH 7.3 prior to use. The buffer of the antibody material was exchanged to 10 mM KH 2 PO 4 through Amicon Ultra-16 centrifugal tube (10 kDa cut-off, Millipore) and the antibody concentration was adjusted approximately at 10 mg/ml. Then 10 mg of the antibody was applied to the column. Antibody species were eluted from the column with linear gradient of 0.2 M a-methyl-D-mannoside (Nacalai Tesque, Kyoto, Japan) over 40 min. Chromatography was repeated until 120 mg of the antibody material were applied to the column.
An LA-LCA column (8.7 ml, 8.6ϫ150 mm; HONEN, Tokyo, Japan) chromatography was carried out using an LC-6A HPLC system (Shimadzu, Kyoto, Japan). Antibody fractions from Con A chromatography were applied to the LA-LCA column equilibrated with 50 mM Tris-H 2 SO 4 at pH 7.3 (buffer A). The amount of antibody applied to the column was 10 mg. The antibodies were eluted with buffer A with linear gradients (0 to 100%) of the buffer containing 0.2 M amethyl-D-mannoside (buffer B) over 50 min. The aimed fractions were collected and subjected to further evaluation. The chromatography was performed at a flow rate of 1.0 ml/min under ambient temperature.
N-Linked Oligosaccharide Profiling Analysis NLinked oligosaccharides were released from 30 mg of IgG by incubation with one unit of recombinant peptide-N-glycosidase F (PNGase F; Sigma-Aldrich) for 18 h at 37°C in 10 mM Tris-acetate (pH 8.3). Reaction was terminated by addition of 350 ml of cold ethanol (final conc. 75%). Then the reaction mixture was vortexed, and centrifuged for 10 min at 12000 rpm at 4°C. The supernatant was transferred to a new tube and dried in vacuo. The glycosylamines released by PNGase F were hydrolyzed to free oligosaccharides in the presence of 13 mM acetic acid at ambient temperature for 2 h. Following hydrolysis, the samples were vacuum dried to remove acetic acid. The resulting samples were finally reconstituted with deionized water and then desalted by spin column (AG50W-X8). The oligosaccharide-containing fraction was dried and analyzed by High Performance Anion Exchange Chromatography (HPAEC) equipped with MALDI-TOF MS. 16) ADCC Assay ADCC activity was determined by a lactate dehydrogenase (LDH) release assay using human peripheral blood mononuclear cells (PBMC) prepared from healthy donors by Lymphoprep (Axis Shield, Dundee, U.K.). MCF-7 cells (purchased from American Type Culture Collection, Manassas, VA, U.S.A.) were used as target cells for antiHer2 antibody. Aliquots of target cells were distributed into 96-well U-bottomed plates (1.0ϫ10 4 cells/50 ml) and incubated with serial dilutions of antibodies (50 ml) in the presence of human effector cells (100 ml) at an E/T ratio of 25 : 1. After incubation for 4 h at 37°C, the supernatant LDH activity was measured using a non-radioactive cytotoxicity assay kit (Promega). The percentage of specific cytolysis was calculated according to the following formula:
Where E is the experimental release (supernatant activity from target cells incubated with antibody and effector cells), S E is spontaneous release in the presence of effector cells (supernatant activity from target cells incubated with effector cells), S T is spontaneous release of target cells (supernatant activity from target cells incubated with medium alone), and M is the maximum release of target cells (activity released from target cells lysed with 9% Triton X-100).
RESULTS AND DISCUSSION
Potential of LA-LCA Chromatography to Enrich Nonfucosylated Antibody Species
The content of non-fucosylated antibody species is not necessarily high in commercial antibody composites. Actually, our oligosaccharide profiling analysis exhibited that non-fucosylated oligosaccharides in anti-Her2 antibody composite accounted for only 5.9% of the total composition (Table 1) . This means that the contribution to the content of antibody species having two arms of nonfucosylated oligosaccharides, that is, completely non-fucosylated antibody species, can be estimated at about one-third of the quantitative value. This level of non-fucosylated oligosaccharides may be insufficient to induce effective ADCC activity for therapeutic purposes. 13, 17) Therefore, we first attempted LA-LCA chromatography in order to know the capability of this type of chromatography for the purification of non-fucosylated antibody species from such antibody material.
As shown in Table 1 , non-fucosylated oligosaccharides were enriched to 44.7% from their initial value (5.9%) by a single LA-LCA chromatography. However, high-mannose oligosaccharides were also enriched to 31.5% in the final fraction. Although high-mannose antibody species exert high-ADCC activity, they are known to have short in vivo half-lives in the body. 18, 19) This implies that the high-mannose antibody species should be controlled within a lower level in desirable high-ADCC antibody composites. But our data suggest that it is difficult to purify non-fucosylated antibody species without concentrating high-mannose oligosaccharides when only LA-LCA chromatography is used. To the best of our knowledge, the isolation and enrichment of nonfucosylated antibody species from the material coexisting high-mannose oligosaccharides using chromatographic technique have not yet been reported, but such a technology, that is, one capable of elevating the ration of non-fucosylated species from antibody composites containing both highly fucosylated and high-mannose species, would be a highly useful tool for preparing the desired high-ADCC antibody composites. So we next tried a combination of Con A and LA-LCA lectin chromatography techniques to develop such a beneficial methodology.
Combination of Con A and LA-LCA Columns to Enrich Non-fucosylated Antibodies from a Typical Antibody Material Con A lectin is known to bind strongly to highmannose oligosaccharides. 20) By taking advantage of Con A chromatography, antibody species with high-mannose oligosaccharides can be eluted with a buffer with a higher amethyl-D-mannoside concentration. Thus, the efficient removal of high-mannose oligosaccharides can be expected by Con A chromatography, and a combination of Con A with LA-LCA may provide a superb means of concentrating nonfucosylated antibody.
In the first Con A chromatography of anti-Her2 antibody composite, the flow-through fraction was designated as Fraction I, and the eluate with a high a-methyl-D-mannoside concentration was designated as Fraction II (Fig. 2A) . The highmannose oligosaccharide content in Fraction I was decreased to 0.6% from 1.7% in the initial material (Table 1) , while the content in Fraction II was enriched to 56.2%, suggesting that high-mannose oligosaccharides were efficiently removed from the material to give Fraction I. In the present study, 1606 Vol. 32, No. 9 Each fraction from Con A and LA-LCA chromatography of anti-Her2 antibody was analyzed by MALDI-TOF MS oligosaccharide profiling.
120 mg of anti-Her2 antibody were injected into the Con A column and subjected to 12 cycles of chromatography, and 100 mg were recovered (83.3% yield) in Fraction I, which was then applied to the LA-LCA column (Fig. 2B) . The nonfucosylated oligosaccharide content in Fraction I (7.1%) was enriched to 61.7% in Fraction III by the introduction of LA-LCA chromatography, while the high-mannose oligosaccharide content was maintained at the lower level of approximately 6% (Table 1) . Finally, we obtained 2.4 mg of antiHer2 antibody composite with concentrated non-fucosylated oligosaccharides in Fraction III. Although the recovery from the LA-LCA column was very low (2.0%), the yield appears to be reasonable, because the initial material contained only 5.9% of non-fucosylated oligosaccharides. ADCC Activity of the Purified Composite In order to elucidate the effectiveness of the combination of separation technologies using Con A and LA-LCA columns, ADCC activity was measured for Fraction III, using the initial antibody material as a reference. As shown in Fig. 3 , the ADCC activity of the isolated composite was significantly elevated. With less than a 1/100 fold concentration of the antibody, the equivalent cytotoxicity was achieved in the purified composite. Based on the results of past investigations, we believe that the elevation of ADCC activity is based on the increased percentage of non-fucosylated antibody species in the purified fraction.
CONCLUSION
We previously established an LA-LCA chromatography to condense non-fucosylated antibody species showing high-ADCC activity from antibody materials produced by the YB2/0 cell line, in which significant levels of fucosylated form exist.
11) LA-LCA chromatography alone, however, failed to enrich non-fucosylated antibodies because of the presence of high-mannose oligosaccharides in the material produced by conventional CHO cell lines. In the present study, we showed that a combination of Con A and LA-LCA lectin affinity columns worked efficiently in purifying nonfucosylated fractions without significantly enriching highmannose oligosaccharides, and the resulting antibody fraction was found to exert high-ADCC activity. Although these two lectin columns are generally used to control oligosaccharide contents by their different affinities, their combination and the separating conditions shown here are easily applied and highly effective to condense non-fucosylated antibody species.
We previously developed FUT8 Ϫ/Ϫ CHO cells capable of producing completely non-fucosylated antibodies, but the preparation of FUT8 Ϫ/Ϫ CHO cells expressing aimed antibodies requires a significant amount of time and effort. As an alternative, the purification strategy described here can be used to prepare non-fucosylated antibody composites. The technology is simple and can be readily applied to any antibody materials independent of production systems such as CHO, NS0 or SP2/0 cells. 
